N-186 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Siemens AG 3t
    3t, supplied by Siemens AG, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/3t/product/Siemens AG
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    3t - by Bioz Stars, 2022-01
    86/100 stars
      Buy from Supplier

    86
    Waters Corporation acquity uplc hhs c18 column
    Acquity Uplc Hhs C18 Column, supplied by Waters Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/acquity uplc hhs c18 column/product/Waters Corporation
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    acquity uplc hhs c18 column - by Bioz Stars, 2022-01
    86/100 stars
      Buy from Supplier

    86
    SCC-Group bcl 2 expression
    Automated Quantitative Analysis (AQUA) of <t>Bcl-2</t> in lung cancer . (A-D) Tumor histospot corresponding to a NSCLC patient with Bcl-2 AQUA score of 400 A. Cytokeratin-Cy3 image used to identify tumor; the epithelial tumor
    Bcl 2 Expression, supplied by SCC-Group, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bcl 2 expression/product/SCC-Group
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bcl 2 expression - by Bioz Stars, 2022-01
    86/100 stars
      Buy from Supplier

    86
    Illumina Inc cpg sites
    Automated Quantitative Analysis (AQUA) of <t>Bcl-2</t> in lung cancer . (A-D) Tumor histospot corresponding to a NSCLC patient with Bcl-2 AQUA score of 400 A. Cytokeratin-Cy3 image used to identify tumor; the epithelial tumor
    Cpg Sites, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cpg sites/product/Illumina Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cpg sites - by Bioz Stars, 2022-01
    86/100 stars
      Buy from Supplier

    Image Search Results


    Automated Quantitative Analysis (AQUA) of Bcl-2 in lung cancer . (A-D) Tumor histospot corresponding to a NSCLC patient with Bcl-2 AQUA score of 400 A. Cytokeratin-Cy3 image used to identify tumor; the epithelial tumor

    Journal: BMC Cancer

    Article Title: High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology

    doi: 10.1186/1471-2407-10-186

    Figure Lengend Snippet: Automated Quantitative Analysis (AQUA) of Bcl-2 in lung cancer . (A-D) Tumor histospot corresponding to a NSCLC patient with Bcl-2 AQUA score of 400 A. Cytokeratin-Cy3 image used to identify tumor; the epithelial tumor "mask" is displayed in C B. Colocalization of subcellular compartments: the non nuclear (green) and nuclear (blue) compartment are defined by the cytokeratin and the DAPI signal respectively D. Bcl-2-Cy5 (red), cytokeratin (green) and DAPI (blue) colocalization; Bcl-2 shows a representative cytoplasmic pattern; AQUA score is inset into the bottom right corner.

    Article Snippet: Validation of cutpoint selection (validation cohort) The cutpoint generated from the training set was applied in the validation cohort and we subsequently assessed the potential of Bcl-2 to predict survival; among all patients tumors with high Bcl-2 expression (n = 186) had a higher median survival compared to the low Bcl-2 expressers (median survival 22 vs. 17.5 months respectively, log rank p = 0.014; Figure ).

    Techniques:

    Distribution and reproducibility of Bcl-2 AQUA scores in cell lines and training set . A. Plotting AQUA scores of the same histospots on serial cuts of the control array stained aside the 2 cohorts at different runs provided a standard curve in order to normalize for run to run variability (Pearson's R = o.96 between runs, p

    Journal: BMC Cancer

    Article Title: High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology

    doi: 10.1186/1471-2407-10-186

    Figure Lengend Snippet: Distribution and reproducibility of Bcl-2 AQUA scores in cell lines and training set . A. Plotting AQUA scores of the same histospots on serial cuts of the control array stained aside the 2 cohorts at different runs provided a standard curve in order to normalize for run to run variability (Pearson's R = o.96 between runs, p

    Article Snippet: Validation of cutpoint selection (validation cohort) The cutpoint generated from the training set was applied in the validation cohort and we subsequently assessed the potential of Bcl-2 to predict survival; among all patients tumors with high Bcl-2 expression (n = 186) had a higher median survival compared to the low Bcl-2 expressers (median survival 22 vs. 17.5 months respectively, log rank p = 0.014; Figure ).

    Techniques: Staining

    Disease outcome by Bcl-2 expression in NSCLC . A, B. Survival curves based on cohort division by the optimal cutpoint generated from the Yale University Cohort (training set); NSCLC and non squamous patients classified as high Bcl-2 expressers (n = 90 and n = 67 respectively) show a benefit towards survival. The distribution of AQUA scores is displayed in inset. C. Kaplan-Meier graphical analysis of survival in NSCLC of the Greek Lung Cancer Cohort (validation set, n = 354). Patients with a high Bcl-2 score (n = 186) had a significant higher median survival compared to the low Bcl-2 group (log rank p = 0.014). The distribution of Bcl-2 AQUA scores is displayed in inset. D. Survival curves for non squamous tumors of the validation cohort classified as high (n = 76) versus low Bcl-2 expressers showed a significant benefit towards survival for the high expressing group (log rank p = 0.04). AQUA; automated quantitative analysis.

    Journal: BMC Cancer

    Article Title: High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology

    doi: 10.1186/1471-2407-10-186

    Figure Lengend Snippet: Disease outcome by Bcl-2 expression in NSCLC . A, B. Survival curves based on cohort division by the optimal cutpoint generated from the Yale University Cohort (training set); NSCLC and non squamous patients classified as high Bcl-2 expressers (n = 90 and n = 67 respectively) show a benefit towards survival. The distribution of AQUA scores is displayed in inset. C. Kaplan-Meier graphical analysis of survival in NSCLC of the Greek Lung Cancer Cohort (validation set, n = 354). Patients with a high Bcl-2 score (n = 186) had a significant higher median survival compared to the low Bcl-2 group (log rank p = 0.014). The distribution of Bcl-2 AQUA scores is displayed in inset. D. Survival curves for non squamous tumors of the validation cohort classified as high (n = 76) versus low Bcl-2 expressers showed a significant benefit towards survival for the high expressing group (log rank p = 0.04). AQUA; automated quantitative analysis.

    Article Snippet: Validation of cutpoint selection (validation cohort) The cutpoint generated from the training set was applied in the validation cohort and we subsequently assessed the potential of Bcl-2 to predict survival; among all patients tumors with high Bcl-2 expression (n = 186) had a higher median survival compared to the low Bcl-2 expressers (median survival 22 vs. 17.5 months respectively, log rank p = 0.014; Figure ).

    Techniques: Expressing, Generated